SCM
REGN icon

Shelton Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Shelton Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.15M Sell
11,459
-6,028
-34% -$4.1M 0.13% 132
2026
Q1 		$13.5M Sell
17,487
-360
-2% -$276K 0.3% 80
2025
Q4 		$13.8M Buy
17,847
+2,860
+19% +$1.94M 0.27% 89
2025
Q3 		$8.43M Sell
14,987
-3,255
-18% -$1.84M 0.18% 117
2025
Q2 		$9.58M Sell
18,242
-236
-1% -$132K 0.22% 106
2025
Q1 		$11.7M Sell
18,478
-547
-3% -$376K 0.28% 95
2024
Q4 		$13.6M Sell
19,025
-180
-0.9% -$151K 0.34% 66
2024
Q3 		$20.2M Sell
19,205
-2,023
-10% -$2.25M 0.52% 34
2024
Q2 		$22.3M Buy
21,228
+226
+1% +$219K 0.61% 29
2024
Q1 		$20.2M Buy
21,002
+5,414
+35% +$5.15M 0.57% 34
2023
Q4 		$13.7M Buy
15,588
+3,349
+27% +$2.76M 0.43% 50
2023
Q3 		$10.1M Buy
12,239
+2,720
+29% +$2.14M 0.37% 59
2023
Q2 		$6.84M Buy
9,519
+400
+4% +$308K 0.25% 97
2023
Q1 		$7.49M Buy
9,119
+673
+8% +$508K 0.31% 85
2022
Q4 		$6.09M Sell
8,446
-1,725
-17% -$1.27M 0.64% 32
2022
Q3 		$7.01M Buy
10,171
+218
+2% +$137K 0.33% 81
2022
Q2 		$5.88M Hold
9,953
– – 0.26% 94
2022
Q1 		$6.95M Sell
9,953
-1,798
-15% -$1.14M 0.26% 92
2021
Q4 		$7.42M Buy
11,751
+424
+4% +$261K 0.26% 87
2021
Q3 		$6.86M Sell
11,327
-1,580
-12% -$981K 0.27% 87
2021
Q2 		$7.21M Hold
12,907
– – 0.27% 83
2021
Q1 		$6.11M Buy
12,907
+4,542
+54% +$2.21M 0.21% 104
2020
Q4 		$4.04M Sell
8,365
-4,001
-32% -$2.16M 0.18% 117
2020
Q3 		$6.92M Buy
12,366
+3,928
+47% +$2.38M 0.29% 72
2020
Q2 		$5.26M Hold
8,438
– – 0.29% 67
2020
Q1 		$4.12M Sell
8,438
-165
-2% -$68.1K 0.3% 67
2019
Q4 		$3.23M Sell
8,603
-234
-3% -$78.7K 0.18% 109
2019
Q3 		$2.45M Sell
8,837
-1,400
-14% -$414K 0.14% 132
2019
Q2 		$3.2M Buy
10,237
+6,329
+162% +$2.11M 0.18% 111
2019
Q1 		$9.52K Sell
3,908
-5,610
-59% -$2.31M 0.04% 412
2018
Q4 		$3.56M Hold
9,518
– – 0.24% 92
2018
Q3 		$3.85M Hold
9,518
– – 0.22% 99
2018
Q2 		$3.28M Hold
9,518
– – 0.2% 107
2018
Q1 		$3.28M Buy
9,518
+1,095
+13% +$381K 0.22% 105
2017
Q4 		$3.17M Hold
8,423
– – 0.2% 107
2017
Q3 		$3.77M Hold
8,423
– – 0.25% 93
2017
Q2 		$4.14M Buy
8,423
+748
+10% +$327K 0.29% 74
2017
Q1 		$2.97M Buy
7,675
+887
+13% +$329K 0.21% 100
2016
Q4 		$2.49M Hold
6,788
– – 0.19% 105
2016
Q3 		$2.73M Sell
6,788
-1
-0% -$401 0.23% 85
2016
Q2 		$2.37M Buy
6,789
+1
+0% +$385 0.21% 92
2016
Q1 		$2.45M Buy
6,788
+601
+10% +$248K 0.22% 91
2015
Q4 		$3.36M Buy
6,187
+219
+4% +$119K 0.32% 63
2015
Q3 		$2.78M Buy
5,968
+436
+8% +$234K 0.31% 68
2015
Q2 		$2.82M Buy
5,532
+189
+4% +$92.2K 0.29% 71
2015
Q1 		$2.41M Buy
5,343
+905
+20% +$384K 0.26% 79
2014
Q4 		$1.82M Buy
4,438
+768
+21% +$302K 0.21% 97
2014
Q3 		$1.32M Buy
3,670
+523
+17% +$175K 0.18% 113
2014
Q2 		$889K Buy
3,147
+221
+8% +$65.5K 0.12% 170
2014
Q1 		$879K Buy
2,926
+251
+9% +$77.3K 0.13% 160
2013
Q4 		$736K Buy
2,675
+114
+4% +$32.8K 0.11% 190
2013
Q3 		$801K Buy
2,561
+678
+36% +$178K 0.13% 160
2013
Q2 		$423K Buy
+1,883
New +$438K 0.08% 324

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Shelton Capital Management's REGN Position: Q2 2026 in Review

Shelton Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 34% in Q2 2026, selling an estimated $4.1M and leaving 11,459 shares worth $7.15M. The position accounts for 0.13% of the portfolio, ranked #132.

Shelton Capital Management first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $22.3M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Shelton Capital Management held 11,459 shares of Regeneron Pharmaceuticals worth $7.15M as of Q2 2026.
  • Shelton Capital Management sold 6,028 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.1M.
  • Regeneron Pharmaceuticals made up 0.13% of Shelton Capital Management's portfolio in Q2 2026, its #132 holding.
  • Shelton Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Shelton Capital Management's Regeneron Pharmaceuticals position peaked at $22.3M in Q2 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Shelton Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.